Anaptys Announces Participation in November and December Investor Conferences
AnaptysBio (ANAB) has announced its participation in four major healthcare investor conferences during November and December 2024. The company's president and CEO Daniel Faga, along with senior management, will participate in fireside chats and one-on-one investor meetings at Guggenheim's Healthcare Innovation Conference (Nov. 13), Stifel Healthcare Conference (Nov. 19), Piper Sandler Healthcare Conference (Dec. 3), and Evercore HealthCONx Conference (Dec. 4). Live webcasts will be available on the company's investor website with replays accessible for 30 days after the events.
AnaptysBio (ANAB) ha annunciato la sua partecipazione a quattro importanti conferenze per investitori nel settore sanitario durante novembre e dicembre 2024. Il presidente e CEO dell'azienda, Daniel Faga, insieme al management senior, parteciperà a discussioni informali e incontri individuali con gli investitori alla Guggenheim's Healthcare Innovation Conference (13 nov), Stifel Healthcare Conference (19 nov), Piper Sandler Healthcare Conference (3 dic) e Evercore HealthCONx Conference (4 dic). Saranno disponibili webcast in diretta sul sito web degli investitori dell'azienda, con registrazioni accessibili per 30 giorni dopo gli eventi.
AnaptysBio (ANAB) ha anunciado su participación en cuatro importantes conferencias de inversores en el ámbito de la salud durante noviembre y diciembre de 2024. El presidente y CEO de la empresa, Daniel Faga, junto con la alta dirección, participará en charlas informales y reuniones individuales con los inversores en la Guggenheim's Healthcare Innovation Conference (13 nov), Stifel Healthcare Conference (19 nov), Piper Sandler Healthcare Conference (3 dic) y Evercore HealthCONx Conference (4 dic). Se ofrecerán transmisiones web en vivo en el sitio web de inversores de la empresa, con repeticiones accesibles durante 30 días después de los eventos.
AnaptysBio (ANAB)는 2024년 11월과 12월에 열리는 네 개의 주요 헬스케어 투자자 회의에 참석한다고 발표했습니다. 회사의 회장 겸 CEO인 다니엘 파가와 고위 경영진은 구겐하임 헬스케어 혁신 회의 (11월 13일), 스티펠 헬스케어 회의 (11월 19일), 파이퍼 샌들러 헬스케어 회의 (12월 3일), 에버코어 헬스CONx 회의 (12월 4일)에서 Fireside Chat과 일대일 투자자 회의를 진행할 것입니다. 회사의 투자자 웹사이트에서 실시간 웹캐스트가 제공되며, 이벤트 후 30일 동안 다시 볼 수 있습니다.
AnaptysBio (ANAB) a annoncé sa participation à quatre grandes conférences pour investisseurs dans le secteur de la santé en novembre et décembre 2024. Le président et CEO de la société, Daniel Faga, ainsi que la direction senior, participeront à des discussions informelles et à des réunions individuelles avec les investisseurs lors de la Guggenheim's Healthcare Innovation Conference (13 nov.), de la Stifel Healthcare Conference (19 nov.), de la Piper Sandler Healthcare Conference (3 déc.) et de la Evercore HealthCONx Conference (4 déc.). Des webcasts en direct seront disponibles sur le site web des investisseurs de l'entreprise, avec des rediffusions accessibles pendant 30 jours après les événements.
AnaptysBio (ANAB) hat seine Teilnahme an vier wichtigen Investorenkonferenzen im Gesundheitswesen angekündigt, die im November und Dezember 2024 stattfinden werden. Der Präsident und CEO des Unternehmens, Daniel Faga, wird zusammen mit dem Senior Management an informellen Gesprächen und persönlichen Treffen mit Investoren auf der Guggenheim's Healthcare Innovation Conference (13. Nov.), der Stifel Healthcare Conference (19. Nov.), der Piper Sandler Healthcare Conference (3. Dez.) und der Evercore HealthCONx Conference (4. Dez.) teilnehmen. Live-Webstreams werden auf der Investorenseite des Unternehmens verfügbar sein, und die Aufzeichnungen sind 30 Tage nach den Veranstaltungen zugänglich.
- None.
- None.
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:
Guggenheim's Inaugural Healthcare Innovation Conference, Boston, MA
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, Nov. 13, 2024 at 1:30pm ET / 10:30am PT
Stifel 2024 Healthcare Conference, New York, NY
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Tuesday, Nov. 19, 2024 at 1:50pm ET / 10:50am PT
Piper Sandler 36th Annual Healthcare Conference, New York, NY
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Tuesday, Dec. 3, 2024 at 2:30pm ET / 11:30am PT
7th Annual Evercore HealthCONx Conference, Coral Gables, FL
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, Dec. 4, 2024 at 1:45pm ET / 10:45am PT
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its pipeline includes two programs targeting co-inhibitory receptors: ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis and rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. It also has other antibodies in its portfolio, including ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, soon to enter clinical development. In addition, Anaptys has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, that has completed Phase 3 trials for the treatment of generalized pustular psoriasis, and etokimab, an anti-IL-33 antagonist that is Phase 2/3 ready. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn and X.
Contact:
Nick Montemarano
Senior Director, Investor Relations and Strategic Communications
858.732.0178
investors@anaptysbio.com
FAQ
When is AnaptysBio (ANAB) presenting at the Guggenheim Healthcare Innovation Conference 2024?
How long will the webcasts of AnaptysBio's (ANAB) investor conference presentations be available?
Which investor conferences will AnaptysBio (ANAB) attend in December 2024?
